Intravenous (IV) proton-pump inhibitors (PPIs) are potent gastric acid suppressing agents, and their use is popular in clinical practice. Both IV and oral PPIs have similarly short half-lives, and their effects on acid secretion are similar, thus their dosing and dosage intervals appear to be interchangeable. The possible exception is when sustained high pHs are required to promote clot stabilization in bleeding peptic ulcers. Continuous infusion appears to be the only form of administration that reliably achieves these high target pHs. IV PPI is indicated in the treatment of high-risk peptic ulcers, complicated gastroesophageal reflux, stress-induced ulcer prophylaxis, Zollinger-Ellison syndrome, and whenever it is impossible or impractical to give oral therapy. The widespread use of PPIs has been controversial. IV PPIs have been linked to the development of nosocomial pneumonia in the intensive care setting and to spontaneous bacterial peritonitis in cirrhotic patients. This review discusses the use of IV PPI in different clinical scenarios, its controversies, and issues of appropriate use.
Afif, W., Alsulaiman, R., Martel, M. and Barkun, A.N. ( 2007) Predictors of inappropriate utilization of intravenous proton pump inhibitors. Aliment Pharmacol Ther25: 609-615.
2.
Ali, T. and Harty, R.F.(2009) Stress-induced ulcer bleeding in critically ill patients. Gastroenterol Clin North Am38: 245-265.
3.
Andriulli, A., Loperfido, S., Focareta, R., Leo, P., Fornari, F., Garripoli, A. et al. (2008) High- versus low-dose proton pump inhibitors after endoscopic hemostasis in patients with peptic ulcer bleeding: a multicentre, randomized study. Am J Gastroenterol103: 3011-3018.
4.
Bajaj, J.S., Dua, K.S., Hanson, K. and Presberg, K. ( 2007) Prospective, randomized trial comparing effect of oral versus intravenous pantoprazole on rebleeding after nonvariceal upper gastrointestinal bleeding: A pilot study. Dig Dis Sci52: 2190-2194.
5.
Bajaj, J.S., Zadvornova, Y., Heuman, D.M., Hafeezullah, M., Hoffmann, R.G., Sanyal, A.J. et al. (2009) Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol104: 1130-1134.
6.
Barkun, A., Bardou, M., Marshall, J.K. and for the Nonvariceal Upper GI Bleeding Consensus Conference Group (2003) Consensus recommendations for managing patients with non-variceal upper gastrointestinal bleeding. Ann Intern Med139: 843-857.
7.
Barkun, A.N., Cockeram, A.W., Ploure, V. and Fedorak, R.N. ( 1999) Review article: acid suppression in non-variceal acute upper gastrointestinal bleeding. Aliment Pharmacol Ther13: 1565-1584.
8.
Barkun, A.N., Herba, K., Adam, V., Kennedy, W., Fallone, C.A. and Bardou, M. ( 2004a) High-dose intravenous proton pump inhibition following endoscopic therapy in the acute management of patients with bleeding peptic ulcers in the USA and Canada: a cost-effective analysis. Aliment Pharmacol Ther19: 591-600.
9.
Barkun, A.N., Herba, K., Adam, V., Kennedy, W., Fallone, C.A. and Bardou, M. ( 2004b) The cost-effectiveness of high-dose oral pump inhibition after endoscopy in the acute treatment of peptic ulcer bleeding. Aliment Pharmacol Ther20: 195-202.
10.
Blatchford, O., Murray, W.R. and Blatchford, M. ( 2000) A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet356: 1318-1321.
11.
British Society of Gastroenterology Endoscopy Committee ( 2002) Non-variceal upper gastrointestinal hemorrhage: Guidelines . Gut51(Suppl. 4): iv1-6.
12.
Cai, Q., Barrie, M., Olejeme, H. and Rosenberg, M.D. ( 2008) A pilot study of efficacy and safety of continuous intravenous infusion of pantoprazole in the treatment of severe erosive esophagitis. Dig Dis Sci53: 1500-1505.
13.
Cook, D., Guyatt, G., Marshall, J., Leasa, D., Fuller, H., Hall, R. et al. (1998) A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med338: 791-797.
14.
Cook, D.J., Fuller, H.D., Guyatt, G.H., Marshall, J.C., Leasa, D., Hall, R. et al. (1994) Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med330: 377-381.
15.
Cook, D.J., Witt, L.G., Cook, R.J. and Guyatt, G.H. ( 1991) Stress ulcer prophylaxis in the critically ill: a meta-analysis . Am J Med91: 519-527.
16.
Czaja, A.J., McAlhany, J.C. and Pruitt Jr, B.A. ( 1974) Acute gastroduodenal disease after thermal injury. An endoscopic evaluation of incidence and natural history. N Engl J Med291: 925-929.
17.
Daneshmend, T.K., Hawkey, C.J., Langman, M.J., Logan, R.F., Long, R.G. and Walt, R.P. ( 1992) Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomized double blind controlled trial. BMJ304: 143-147.
18.
Dekkers, C.P., Beker, J.A., Thjodleifsson, B., Gabryelewicz, A., Bell, N.E. and Humphries, T.J. ( 1999) Double-blind comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther13: 49-57.
19.
Ellison, R.T., Perez-Perez, G., Welsh, C.H., Blaser, M.J., Riester, K.A., Cross, A.S. et al. (1996) Risk factors for upper gastrointestinal bleeding in intensive care unit patients: role of helicobacter pylori. Federal Hyperimmune Imunoglobulin Therapy Study Group. Crit Care Med24: 1974-1981.
20.
Enns, R.A., Gagnon, Y.M., Rioux, K.P. and Levy, A.R. ( 2003) Cost-effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding . Aliment Pharmacol Ther17: 225-233.
21.
Erstad, B.L. ( 2004) Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding. Crit Care Med32: 1277-1283.
22.
Furuta, T., Ohashi, K., Kamata, T., Takashima, M., Kosuge, K., Kawasaki, T. et al. (1998) Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer . Ann Intern Med129: 1027-1230.
23.
Furuta, T., Shirai, N., Sugimoto, M., Nakamura, A., Hishida, A. and Ishizaki, T. ( 2005) Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet20: 153-167.
24.
Gardner, T.B. and Robertson, D.J. ( 2006) Stress ulcer prophylaxis in non-critically ill patients: less may be more. Am J Gastroenterol101: 2206-2208.
25.
Guda, N.M., Noonan, M., Kreiner, M.J., Partington, S. and Vakil, N. ( 2004) Use of intravenous proton pump inhibitors in community practice: an explanation for the shortage? Am J Gastroenterol99: 1233-1237.
26.
Hartmann, M., Ehrlich, A., Fuder, H., Luhmann, R., Emeklibas, S., Timmer, W. et al. (1998) Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole. Aliment Pharmacol Ther12: 1027-1032.
27.
Hasselgren, G., Lind, T., Lundell, L., Aadland, E., Efskind, P., Falk, A. et al. (1997) Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding. Results of a placebo-controlled multicenter study. Scand J Gastroenterol32: 328-333.
28.
Herzig, S.J., Howell, M.D., Ngo, L.H. and Marcantonio, E.R.(2009) Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA301: 2120-2128.
29.
Javid, G., Zargar, S.A., U-Saif, R., Khan, B.A., Yatoo, G.N., Shah, A.H. et al. (2009) Comparison of p.o. and i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer. J Gastroenterol Hepatol24: 1236-1243.
30.
Jensen, D.M., Pace, S.C., Soffer, E., Comer, G.M. and 315 Study Group (2006) Continuous infusion of pantoprazole versus ranitidine for prevention of ulcer rebleeding; a U.S. multicenter, randomized, double-blind study. Am J Gastroenterol101: 1991-1999.
31.
Julapalli, V.R. and Graham, D.Y. ( 2005) Appropriate use of intravenous proton pump inhibitors in the management of bleeding peptic ulcer. Dig Dis Sci50: 1185-1193.
32.
Kahi, C.J., Jensen, D.M., Sung, J.J., Bleau, B.L., Jung, H.K., Eckert, G. et al. (2005) Endoscopic therapy versus medical therapy for bleeding peptic ulcer with adherent clot: a meta-analysis. Gastroenterology129: 855-862.
33.
Kaplan, G.G., Bates, D., McDonald, D., Panaccione, R. and Romagnuolo, J. ( 2005) Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions. Clin Gastroenterol Hepatol3: 1207-1214.
Kovacs, T.O., Lee, C.Q., Chiu, Y.L., Pilmer, B.L. and Metz, D.C. ( 2004) Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis. Aliment Pharmacol Ther20: 883-889.
36.
Laine, L. and Peterson, W. ( 1994) Bleeding peptic ulcer. N Engl J Med331: 717-727.
37.
Laine, L., Shah, A. and Bemanian, S. ( 2008) Intragastric pH with oral vs intravenous bolus plus infusion pump inhibitor therapy in patients with bleeding ulcers. Gastroenterology134: 1836-1841.
38.
Laine, L., Stein, C. and Sharma, V. ( 1996) A prospective outcome study of patients with clot in an ulcer and the effect of irrigation. Gastrointest Endosc43: 107-110.
39.
Lau, J.Y., Leung, W.K., Wu, J.C., Chan, F.K., Wong, V.W., Chiu, P.W. et al. (2007) Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med356: 1631-1640.
40.
Lau, J.Y., Sung, J.J., Lee, K.K., Yung, M.Y., Wong, S.K., Wu, J.C. et al. (2000) Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med343: 310-316.
Lew, E.A., Pisegna, J.R., Starr, J.A., Soffer, E.F., Forsmark, C. and Modlin, I.M. ( 2000) Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology118: 696-704.
43.
Lin, H.J., Lo, W.C., Chen, Y.C. and Perng, C.L. ( 2006) Role of intravenous omeprazole in patients with high-risk of peptic ulcer bleeding after successful endoscopic epinephrine injection: A prospective randomized comparative trial. Am J Gastroenterol101: 500-505.
44.
Lin, M.S., Sun, P. and Yu, H.Y. ( 1998) Evaluation of buffering capacity and acid neutralizing-pH time profile of antacids. J Formos Med Assoc97: 704-710.
45.
Maton, P.N. ( 1996) Zollinger-Ellison syndrome. Recognition and management of acid hypersecretion. Drugs52: 33-44.
46.
Merki, H.S. and Wilder-Smith, C.H. ( 1994) Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology106: 60-64.
47.
Messori, A., Trippoli, S., Vaiani, M., Gorini, M. and Corrado, A. ( 2000) Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomized controlled trials. BMJ321: 1103-1106.
48.
Metz, D.C., Amer, F., Hunt, B., Vakily, M., Kukulka, M.J. and Samra, N. ( 2006) Lansoprazole regimens that sustain intragastric pH >6: an evaluation of intermittent oral and continuous intravenous lansoprazole or ranitidine. Aliment Pharmacol Ther23: 985-995.
49.
Metz, D.C., Forsmark, C., Lew, E.A., Starr, J.A., Soffer, E.F., Bochenek, W. et al. (2001) Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Am J Gastroenterol96: 3274-3280.
50.
Metz, D.C., Pratha, V., Martin, P., Paul, J., Maton, P.N., Lew, E. et al. (2000) Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. Am J Gastroenterol95: 626-633.
51.
Metz, D.C., Soffer, E., Forsmark, C.E., Cryer, B., Chey, W., Bochenek, W. et al. (2003) Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion . Am J Gastroenterol98: 310-317.
52.
Miano, T.A., Reichert, M.G., Houle, T.T., MacGregor, D.A., Kincaid, E.H. and Bowton, D.L.(2009) Nosocomial pneumonia risk and stress ulcer prophylaxis: a comparison of pantoprazole vs ranitidine in cardiothoracic surgery patients. Chest136: 440-447.
53.
Mutlu, G.M., Mutlu, E.A. and Factor, P. ( 2001) GI complications in patients receiving mechanical ventilation . Chest119: 1222-1241.
54.
Ostro, M.J., Russell, J.A., Soldin, S.J., Mahon, W.A. and Jeejeebhoy, K.N. ( 1985) Control of gastric pH with cimetidine: boluses versus primed infusions. Gastroenterology89: 532-537.
55.
Package insert. Nexium IV (esomeprazole). Wilmington, DE: Astra-Zeneca PLC. Available at: http://www.1.astrazeneca-us.com/pi/nexium_iv.pdf , accessed 5 July 2009.
56.
Package insert. Prevacid IV (lansoprazole). Lake Forest, IL: TAP Pharmaceutical Products. http://pitap.abbott.com/prevacidiv.pdf?noCache=,accessed5July2009.
57.
Package insert. Protonix IV (pantoprazole). Madison, WI : Wyeth Pharmaceuticals. http://www.wyeth.com/content/showlabeling.asp?id=469, accessed 5 July 2009.
58.
Peura, D.A. and Johnson, L.F. ( 1985) Cimetidine for prevention and treatment of gastroduodenal mucosal lesions in patients in an intensive care unit. Ann Intern Med103: 173-177.
59.
Quenot, J.P., Thiery, N. and Barbar, S.(2009) When should stress ulcer prophylaxis be used in the ICU?Curr Opin Crit Care15: 139-143.
60.
Richardson, P., Hawkey, C.J. and Stack, W.A. ( 1998) Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs56: 307-335.
61.
Richter, J.E. and Bochenek, W. ( 2000) Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol95: 3071-3080.
Saeed, Z.A., Ramirez, F.C., Hepps, K.S., Cole, R.A. and Graham, D.Y. ( 1995) Prospective validation of the Baylor bleeding score for predicting the likelihood of rebleeding after endoscopic hemostasis of peptic ulcers. Gastrointest Endosc41: 561-565.
64.
Sagar, M., Tybring, G., Dahl, M.L., Bertilsson, L. and Seensalu, R. ( 2000) Effects of omperazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. Gastroenterology119: 670-676.
65.
Schaffalitzky de Muckadell, O.B. , Havelund, T., Harling, H., Boesby, S., Snel, P., Vreeburg, E.M. et al. (1997) Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers. Randomized double-blind placebo-controlled multicentre study. Scand J Gastroenterol32: 320-327.
66.
Siepler, J.K., Trudeau, W. and Petty, D.E. ( 1989) Use of continuous infusion of histamine 2-receptor antagonists in critically ill patients. DICP23: S40-43.
67.
Simmons, T.C., Hogan, D.L., Selling, J.A., Maxwell, V. and Isenberg, J.I. ( 1986) The effect of sodium bicarbonate versus aluminium-magnesium hydroxide on postprandial gastric acid in duodenal ulcer patients. J Clin Gastroenterol8: 146-149.
68.
Somberg, L., Morris Jr, J., Fantus, R., Graepel, J., Field, B.G., Lynn, R. et al. (2008) Intermittent intravenous pantoprazole and continuous cimetidine infusion: effect on gastric pH control in critically ill patients at risk of developing stress-related mucosal disease. J Trauma64: 1202-1210.
69.
Stanley, A.J., Ashley, D., Dalton, H.R., Mowat, C., Gaya, D.R., Thompson, E. et al. (2009) Outpatient management of patients with low-risk upper gastrointestinal haemorrhage: multicentre validation and prospective evaluation. Lancet373: 42-47.
70.
Sugimoto, M., Furuta, T., Shirai, N., Ikuma, M., Hishida, A. and Ishizaki, T. ( 2006) Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther80: 539-548.
71.
Sung, J.J.Y., Barkun, A., Kuipers, E.J., Mossner, J., Jensen, D.M., Stuart, R. et al. and for the Peptic Ulcer Bleed Study Group ( 2009) Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med150: 455-464.
72.
Sung, J.Y., Chan, F.K., Lau, J.Y., Yung, M.Y., Leung, W.K., Wu, J.C. et al. (2003) The effect of endoscopic therapy in patients receiving omeprazole for bleeding ulcer with nonbleeding visible vessels or adherent clots. A randomized comparison. Ann Intern Med139: 237-243.
73.
Thorens, J., Froehlich, F., Schwizer, W., Saraga, E., Bille, J., Gyr, K. et al. (1996) Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomized double blind study. Gut39: 54-59.
74.
Tsoi, K.K.F., Lau, J.Y.W. and Sung, J.J.Y. ( 2008) Cost-effective analysis of high-dose omeprazole infusion before endoscopy for patients with upper-GI bleeding. Gastrointest Endosc67: 1056-1063.
75.
Udd, M., Miettinen, P., Palmu, A., Heikkinen, M., Janatuinen, E., Pasanen, P. et al. (2001) Regular-dose versus high-dose omeprazole in peptic ulcer bleeding: A prospective randomized double-blind study. Scand J Gastroenterol36: 1332-1338.
76.
Vinayek, R., Hahne, W.F., Euler, A.R., Norton, J.A. and Jensen, R.T. ( 1993) Parenteral control of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Dig Dis Sci38: 1857-1865.
77.
Welage, L.S. ( 2003) Pharmacologic features of proton pump inhibitors and their potential relevance to clinical practice. Gastroenterol Clin North Am32: S25-35.
78.
Wohlt, P.D., Hansen, L.A. and Fish, J.T. ( 2007) Inappropriate continuation of stress ulcer prophylactic therapy after discharge. Ann Pharmacother41: 1611-1616.
79.
Zargar, S.A., Javid, G., Khan, B.A., Yattoo, G.N., Shah, A.H., Gulzar, G.M. et al. (2006) Pantoprazole infusion as adjuvant therapy to endoscopic treatment in patients with peptic ulcer bleeding: prospective randomized controlled trial. J Gastroenterol Hepatol21: 716-721.
